HPTN 084 study: CAB LA superior to oral FTC/TDF for HIV prevention

KUALA LUMPUR, Nov 10 -- HIV Prevention Trials Network (HPTN) researchers have announced HPTN 084 clinical trial data indicates a pre-exposure prophylaxis regimen of long-acting cabotegravir (CAB LA) injections once every eight weeks was safe and superior to daily oral tenofovir/emtricitabine (FTC/TDF) for HIV prevention among cisgender women in sub-Saharan Africa.

During a planned review of study data, an independent Data and Safety Monitoring Board (DSMB) recommended the study sponsor―the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health―stop the blinded phase of the trial and share the results. The study was originally designed to continue through 2022.

HPTN 084 study: CAB LA superior to oral FTC/TDF for HIV prevention: HPTN 084 study: CAB LA superior to oral FTC/TDF fo